Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Gregucci, F. Spada, S. Barcellos-Hoff, M.H. Bhardwaj, N. Chan Wah Hak, C. Fiorentino, A. Guha, C. Guzman, M.L. Harrington, K. Herrera, F.G. Honeychurch, J. Hong, T. Iturri, L. Jaffee, E. Karam, S.D. Knott, S.R. Koumenis, C. Lyden, D. Marciscano, A.E. Melcher, A. Mondini, M. Mondino, A. Morris, Z.S. Pitroda, S. Quezada, S.A. Santambrogio, L. Shiao, S. Stagg, J. Telarovic, I. Timmerman, R. Vozenin, M.-. Weichselbaum, R. Welsh, J. Wilkins, A. Xu, C. Zappasodi, R. Zou, W. Bobard, A. Demaria, S. Galluzzi, L. Deutsch, E. Formenti, S.C. (2023). Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology, Vol.12 (1), p. 2222560.  show abstract

Bozhanova, G. Hassan, J. Appleton, L. Jennings, V. Foo, S. McLaughlin, M. Chan Wah Hak, C.M. Patin, E.C. Crespo-Rodriguez, E. Baker, G. Armstrong, E. Chiu, M. Pandha, H. Samson, A. Roulstone, V. Kyula, J. Vile, R. Errington-Mais, F. Pedersen, M. Harrington, K. Ono, M. Melcher, A. (2022). CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma. J immunother cancer, Vol.10 (3).  show abstract

Patin, E.C. Dillon, M.T. Nenclares, P. Grove, L. Soliman, H. Leslie, I. Northcote, D. Bozhanova, G. Crespo-Rodriguez, E. Baldock, H. Whittock, H. Baker, G. Kyula, J. Guevara, J. Melcher, A.A. Harper, J. Ghadially, H. Smith, S. Pedersen, M. McLaughlin, M. Harrington, K.J. (2022). Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J immunother cancer, Vol.10 (3).  show abstract

Samson, A. West, E.J. Carmichael, J. Scott, K.J. Turnbull, S. Kuszlewicz, B. Dave, R.V. Peckham-Cooper, A. Tidswell, E. Kingston, J. Johnpulle, M. da Silva, B. Jennings, V.A. Bendjama, K. Stojkowitz, N. Lusky, M. Prasad, K.R. Toogood, G.J. Auer, R. Bell, J. Twelves, C.J. Harrington, K.J. Vile, R.G. Pandha, H. Errington-Mais, F. Ralph, C. Newton, D.J. Anthoney, A. Melcher, A.A. Collinson, F. (2022). Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer immunol res, Vol.10 (6), pp. 745-756.  show abstract

Wilkins, A. Hall, E. Lewis, R. Gribble, H. Melcher, A. Huddart, R. RE-ARM Trial Management Group, (2022). RE-ARMing the Immune Response to Bladder Cancer with Radiotherapy. Clin oncol (r coll radiol), Vol.34 (7), pp. 421-425.

Korlimarla, A. Ps, H. Prabhu, J. Ragulan, C. Patil, Y. Vp, S. Desai, K. Mathews, A. Appachu, S. Diwakar, R.B. Bs, S. Melcher, A. Cheang, M. Sadanandam, A. (2022). Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. Transl oncol, Vol.25, p. 101511.  show abstract

Murray, J. Cruickshank, C. Bird, T. Bell, P. Braun, J. Chuter, D. Ferreira, M.R. Griffin, C. Hassan, S. Hujairi, N. Melcher, A. Miles, E. Naismith, O. Panades, M. Philipps, L. Reid, A. Rekowski, J. Sankey, P. Staffurth, J. Syndikus, I. Tree, A. Wilkins, A. Hall, E. PEARLS Trial Management Group, (2022). PEARLS - A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and/or para-aortic lymph nodes at presentation. Clin transl radiat oncol, Vol.37, pp. 130-136.  show abstract

Evgin, L. Kottke, T. Tonne, J. Thompson, J. Huff, A.L. van Vloten, J. Moore, M. Michael, J. Driscoll, C. Pulido, J. Swanson, E. Kennedy, R. Coffey, M. Loghmani, H. Sanchez-Perez, L. Olivier, G. Harrington, K. Pandha, H. Melcher, A. Diaz, R.M. Vile, R.G. (2022). Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci transl med, Vol.14 (640), p. eabn2231.  show abstract

Gazinska, P. Milton, C. Iacovacci, J. Ward, J. Buus, R. Alaguthurai, T. Graham, R. Akarca, A. Lips, E. Naidoo, K. Wesseling, J. Marafioti, T. Cheang, M. Gillett, C. Wu, Y. Khan, A. Melcher, A. Salgado, R. Dowsett, M. Tutt, A. Roxanis, I. Haider, S. Irshad, S. (2022). Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers. Clin cancer res, Vol.28 (20), pp. 4494-4508.  show abstract

West, E.J. Scott, K.J. Tidswell, E. Bendjama, K. Stojkowitz, N. Lusky, M. Kurzawa, M. Prasad, R. Toogood, G. Ralph, C. Anthoney, D.A. Melcher, A.A. Collinson, F.J. Samson, A. (2022). Intravenous Oncolytic Vaccinia Virus Therapy Results in a Differential Immune Response between Cancer Patients. Cancers (basel), Vol.14 (9).  show abstract

Schuelke, M.R. Gundelach, J.H. Coffey, M. West, E. Scott, K. Johnson, D.R. Samson, A. Melcher, A. Vile, R.G. Bram, R.J. (2022). Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neurooncol adv, Vol.4 (1), p. vdac085.  show abstract

Melake, M.J. Smith, H.G. Mansfield, D. Davies, E. Dillon, M.T. Wilkins, A.C. Patin, E.C. Pedersen, M. Buus, R. Melcher, A.A. Thway, K. Miah, A.B. Zaidi, S.H. Hayes, A.J. Fenton, T.R. Harrington, K.J. McLaughlin, M. (2022). OX40 and 4-1BB delineate distinct immune profiles in sarcoma. Oncoimmunology, Vol.11 (1), p. 2066050.  show abstract

Andreou, T. Williams, J. Brownlie, R.J. Salmond, R.J. Watson, E. Shaw, G. Melcher, A. Wurdak, H. Short, S.C. Lorger, M. (2021). Hematopoietic stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model. J immunother cancer, Vol.9 (3).  show abstract

Müller, L.M. Migneco, G. Scott, G.B. Down, J. King, S. Askar, B. Jennings, V. Oyajobi, B. Scott, K. West, E. Ralph, C. Samson, A. Ilett, E.J. Muthana, M. Coffey, M. Melcher, A. Parrish, C. Cook, G. Lawson, M. Errington-Mais, F. (2021). Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. J immunother cancer, Vol.9 (3).  show abstract

Wilkins, A. Fontana, E. Nyamundanda, G. Ragulan, C. Patil, Y. Mansfield, D. Kingston, J. Errington-Mais, F. Bottomley, D. von Loga, K. Bye, H. Carter, P. Tinkler-Hundal, E. Noshirwani, A. Downs, J. Dillon, M. Demaria, S. Sebag-Montefiore, D. Harrington, K. West, N. Melcher, A. Sadanandam, A. (2021). Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. J immunother cancer, Vol.9 (3).  show abstract

Challoner, B.R. von Loga, K. Woolston, A. Griffiths, B. Sivamanoharan, N. Semiannikova, M. Newey, A. Barber, L.J. Mansfield, D. Hewitt, L.C. Saito, Y. Davarzani, N. Starling, N. Melcher, A. Grabsch, H.I. Gerlinger, M. (2021). Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. J natl cancer inst, Vol.113 (1), pp. 88-98.  show abstract

Nenclares, P. Gunn, L. Soliman, H. Bover, M. Trinh, A. Leslie, I. Wong, K.H. Melcher, A. Newbold, K. Nutting, C.M. Ap Dafydd, D. Bhide, S.A. Harrington, K. (2021). On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy. J immunother cancer, Vol.9 (6).  show abstract

Roulstone, V. Mansfield, D. Harris, R.J. Twigger, K. White, C. de Bono, J. Spicer, J. Karagiannis, S.N. Vile, R. Pandha, H. Melcher, A. Harrington, K. (2021). Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. J immunother cancer, Vol.9 (7).  show abstract

Young, K. Lawlor, R.T. Ragulan, C. Patil, Y. Mafficini, A. Bersani, S. Antonello, D. Mansfield, D. Cingarlini, S. Landoni, L. Pea, A. Luchini, C. Piredda, L. Kannan, N. Nyamundanda, G. Morganstein, D. Chau, I. Wiedenmann, B. Milella, M. Melcher, A. Cunningham, D. Starling, N. Scarpa, A. Sadanandam, A. (2021). Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, Vol.70 (10), pp. 1904-1913.  show abstract

Vile, R.G. Melcher, A. Pandha, H. Harrington, K.J. Pulido, J.S. (2021). APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable. Clin cancer res, Vol.27 (12), pp. 3280-3290.  show abstract

Kottke, T. Tonne, J. Evgin, L. Driscoll, C.B. van Vloten, J. Jennings, V.A. Huff, A.L. Zell, B. Thompson, J.M. Wongthida, P. Pulido, J. Schuelke, M.R. Samson, A. Selby, P. Ilett, E. McNiven, M. Roberts, L.R. Borad, M.J. Pandha, H. Harrington, K. Melcher, A. Vile, R.G. (2021). Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nat commun, Vol.12 (1), p. 1930.  show abstract

Annels, N.E. Simpson, G.R. Denyer, M. Arif, M. Coffey, M. Melcher, A. Harrington, K. Vile, R. Pandha, H. (2021). Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors. Mol ther oncolytics, Vol.20, pp. 434-446.  show abstract

Appleton, E. Hassan, J. Chan Wah Hak, C. Sivamanoharan, N. Wilkins, A. Samson, A. Ono, M. Harrington, K.J. Melcher, A. Wennerberg, E. (2021). Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Front immunol, Vol.12, p. 754436.  show abstract

Galluzzi, L. Vitale, I. Warren, S. Adjemian, S. Agostinis, P. Martinez, A.B. Chan, T.A. Coukos, G. Demaria, S. Deutsch, E. Draganov, D. Edelson, R.L. Formenti, S.C. Fucikova, J. Gabriele, L. Gaipl, U.S. Gameiro, S.R. Garg, A.D. Golden, E. Han, J. Harrington, K.J. Hemminki, A. Hodge, J.W. Hossain, D.M. Illidge, T. Karin, M. Kaufman, H.L. Kepp, O. Kroemer, G. Lasarte, J.J. Loi, S. Lotze, M.T. Manic, G. Merghoub, T. Melcher, A.A. Mossman, K.L. Prosper, F. Rekdal, Ø. Rescigno, M. Riganti, C. Sistigu, A. Smyth, M.J. Spisek, R. Stagg, J. Strauss, B.E. Tang, D. Tatsuno, K. van Gool, S.W. Vandenabeele, P. Yamazaki, T. Zamarin, D. Zitvogel, L. Cesano, A. Marincola, F.M. (2020). Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J immunother cancer, Vol.8 (1).  show abstract

Close, H.J. Stead, L.F. Nsengimana, J. Reilly, K.A. Droop, A. Wurdak, H. Mathew, R.K. Corns, R. Newton-Bishop, J. Melcher, A.A. Short, S.C. Cook, G.P. Wilson, E.B. (2020). Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clin exp immunol, Vol.200 (1), pp. 33-44.  show abstract

McLaughlin, M. Patin, E.C. Pedersen, M. Wilkins, A. Dillon, M.T. Melcher, A.A. Harrington, K.J. (2020). Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat rev cancer, Vol.20 (4), pp. 203-217.  show abstract

Nenclares, P. Bhide, S.A. Sandoval-Insausti, H. Pialat, P. Gunn, L. Melcher, A. Newbold, K. Nutting, C.M. Harrington, K.J. (2020). Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. Eur j cancer, Vol.131, pp. 9-15.  show abstract

Chiu, M. Armstrong, E.J. Jennings, V. Foo, S. Crespo-Rodriguez, E. Bozhanova, G. Patin, E.C. McLaughlin, M. Mansfield, D. Baker, G. Grove, L. Pedersen, M. Kyula, J. Roulstone, V. Wilkins, A. McDonald, F. Harrington, K. Melcher, A. (2020). Combination therapy with oncolytic viruses and immune checkpoint inhibitors. Expert opin biol ther, Vol.20 (6), pp. 635-652.  show abstract

Driscoll, C.B. Schuelke, M.R. Kottke, T. Thompson, J.M. Wongthida, P. Tonne, J.M. Huff, A.L. Miller, A. Shim, K.G. Molan, A. Wetmore, C. Selby, P. Samson, A. Harrington, K. Pandha, H. Melcher, A. Pulido, J.S. Harris, R. Evgin, L. Vile, R.G. (2020). APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy. Nat commun, Vol.11 (1), p. 790.  show abstract

Arwert, E.N. Milford, E.L. Rullan, A. Derzsi, S. Hooper, S. Kato, T. Mansfield, D. Melcher, A. Harrington, K.J. Sahai, E. (2020). STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy. Nat cell biol, Vol.22 (7), pp. 758-766.  show abstract

Crespo-Rodriguez, E. Bergerhoff, K. Bozhanova, G. Foo, S. Patin, E.C. Whittock, H. Buus, R. Haider, S. Muirhead, G. Thway, K. Newbold, K. Coffin, R.S. Vile, R.G. Kim, D. McLaughlin, M. Melcher, A.A. Harrington, K.J. Pedersen, M. (2020). Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer. J immunother cancer, Vol.8 (2).  show abstract

Smith, H.G. Jamal, K. Dayal, J.H. Tenev, T. Kyula-Currie, J. Guppy, N. Gazinska, P. Roulstone, V. Liccardi, G. Davies, E. Roxanis, I. Melcher, A.A. Hayes, A.J. Inman, G.J. Harrington, K.J. Meier, P. (2020). RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. Embo mol med, Vol.12 (6), p. e10979.  show abstract

Sadanandam, A. Bopp, T. Dixit, S. Knapp, D.J. Emperumal, C.P. Vergidis, P. Rajalingam, K. Melcher, A. Kannan, N. (2020). A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. Cell death discov, Vol.6 (1), p. 141.  show abstract

McLaughlin, M. Pedersen, M. Roulstone, V. Bergerhoff, K.F. Smith, H.G. Whittock, H. Kyula, J.N. Dillon, M.T. Pandha, H.S. Vile, R. Melcher, A.A. Harrington, K.J. (2020). The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism. Mol ther oncolytics, Vol.16, pp. 238-249.  show abstract

Punta, M. Jennings, V.A. Melcher, A.A. Lise, S. (2020). The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: An In Silico Study. Front immunol, Vol.11, p. 524968.  show abstract

Smith, H.G. Mansfield, D. Roulstone, V. Kyula-Currie, J.N. McLaughlin, M. Patel, R.R. Bergerhoff, K.F. Paget, J.T. Dillon, M.T. Khan, A. Melcher, A. Thway, K. Harrington, K.J. Hayes, A.J. (2019). PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma. Clin cancer res, Vol.25 (11), pp. 3443-3454.  show abstract

Annels, N.E. Mansfield, D. Arif, M. Ballesteros-Merino, C. Simpson, G.R. Denyer, M. Sandhu, S.S. Melcher, A.A. Harrington, K.J. Davies, B. Au, G. Grose, M. Bagwan, I. Fox, B. Vile, R. Mostafid, H. Shafren, D. Pandha, H.S. (2019). Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. Clin cancer res, Vol.25 (19), pp. 5818-5831.  show abstract

Müller, L.M. Holmes, M. Michael, J.L. Scott, G.B. West, E.J. Scott, K.J. Parrish, C. Hall, K. Stäble, S. Jennings, V.A. Cullen, M. McConnell, S. Langton, C. Tidswell, E.L. Shafren, D. Samson, A. Harrington, K.J. Pandha, H. Ralph, C. Kelly, R.J. Cook, G. Melcher, A.A. Errington-Mais, F. (2019). Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. J immunother cancer, Vol.7 (1), p. 164.  show abstract

Dillon, M.T. Bergerhoff, K.F. Pedersen, M. Whittock, H. Crespo-Rodriguez, E. Patin, E.C. Pearson, A. Smith, H.G. Paget, J.T. Patel, R.R. Foo, S. Bozhanova, G. Ragulan, C. Fontana, E. Desai, K. Wilkins, A.C. Sadanandam, A. Melcher, A. McLaughlin, M. Harrington, K.J. (2019). ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clin cancer res, Vol.25 (11), pp. 3392-3403.  show abstract

Wilkins, A.C. Patin, E.C. Harrington, K.J. Melcher, A.A. (2019). The immunological consequences of radiation-induced DNA damage. J pathol, Vol.247 (5), pp. 606-614.  show abstract

Jennings, V.A. Scott, G.B. Rose, A.M. Scott, K.J. Migneco, G. Keller, B. Reilly, K. Donnelly, O. Peach, H. Dewar, D. Harrington, K.J. Pandha, H. Samson, A. Vile, R.G. Melcher, A.A. Errington-Mais, F. (2019). Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Mol ther, Vol.27 (6), pp. 1139-1152.  show abstract

Evgin, L. Huff, A.L. Kottke, T. Thompson, J. Molan, A.M. Driscoll, C.B. Schuelke, M. Shim, K.G. Wongthida, P. Ilett, E.J. Smith, K.K. Harris, R.S. Coffey, M. Pulido, J.S. Pandha, H. Selby, P.J. Harrington, K.J. Melcher, A. Vile, R.G. (2019). Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment. Cancer immunol res, Vol.7 (5), pp. 828-840.  show abstract

Wilkins, A. McDonald, F. Harrington, K. Melcher, A. (2019). Radiotherapy enhances responses of lung cancer to CTLA-4 blockade. J immunother cancer, Vol.7 (1), p. 64.  show abstract

Gonzalez-Exposito, R. Semiannikova, M. Griffiths, B. Khan, K. Barber, L.J. Woolston, A. Spain, G. von Loga, K. Challoner, B. Patel, R. Ranes, M. Swain, A. Thomas, J. Bryant, A. Saffery, C. Fotiadis, N. Guettler, S. Mansfield, D. Melcher, A. Powles, T. Rao, S. Watkins, D. Chau, I. Matthews, N. Wallberg, F. Starling, N. Cunningham, D. Gerlinger, M. (2019). CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J immunother cancer, Vol.7 (1), p. 101.  show abstract

Samson, A. Bentham, M.J. Scott, K. Nuovo, G. Bloy, A. Appleton, E. Adair, R.A. Dave, R. Peckham-Cooper, A. Toogood, G. Nagamori, S. Coffey, M. Vile, R. Harrington, K. Selby, P. Errington-Mais, F. Melcher, A. Griffin, S. (2018). Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, Vol.67 (3), pp. 562-573.  show abstract

Samson, A. Scott, K.J. Taggart, D. West, E.J. Wilson, E. Nuovo, G.J. Thomson, S. Corns, R. Mathew, R.K. Fuller, M.J. Kottke, T.J. Thompson, J.M. Ilett, E.J. Cockle, J.V. van Hille, P. Sivakumar, G. Polson, E.S. Turnbull, S.J. Appleton, E.S. Migneco, G. Rose, A.S. Coffey, M.C. Beirne, D.A. Collinson, F.J. Ralph, C. Alan Anthoney, D. Twelves, C.J. Furness, A.J. Quezada, S.A. Wurdak, H. Errington-Mais, F. Pandha, H. Harrington, K.J. Selby, P.J. Vile, R.G. Griffin, S.D. Stead, L.F. Short, S.C. Melcher, A.A. (2018). Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Sci transl med, Vol.10 (422).  show abstract

Comins, C. Simpson, G.R. Rogers, W. Relph, K. Harrington, K. Melcher, A. Roulstone, V. Kyula, J. Pandha, H. (2018). Synergistic antitumour effects of rapamycin and oncolytic reovirus. Cancer gene ther, Vol.25 (5-6), pp. 148-160.  show abstract

Wilkins, A. Melcher, A. Somaiah, N. (2018). Science in Focus: Biological Optimisation of Radiotherapy Fraction Size in an Era of Immune Oncology. Clin oncol (r coll radiol), Vol.30 (10), pp. 605-608.

Berkeley, R.A. Steele, L.P. Mulder, A.A. van den Wollenberg, D.J. Kottke, T.J. Thompson, J. Coffey, M. Hoeben, R.C. Vile, R.G. Melcher, A. Ilett, E.J. (2018). Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer immunol res, Vol.6 (10), pp. 1161-1173.  show abstract

Taggart, D. Andreou, T. Scott, K.J. Williams, J. Rippaus, N. Brownlie, R.J. Ilett, E.J. Salmond, R.J. Melcher, A. Lorger, M. (2018). Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking. Proc natl acad sci u s a, Vol.115 (7), pp. E1540-E1549.  show abstract

Huff, A.L. Wongthida, P. Kottke, T. Thompson, J.M. Driscoll, C.B. Schuelke, M. Shim, K.G. Harris, R.S. Molan, A. Pulido, J.S. Selby, P.J. Harrington, K.J. Melcher, A. Evgin, L. Vile, R.G. (2018). APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol ther oncolytics, Vol.11, pp. 1-13.  show abstract

Khan, A.A. Paget, J.T. McLaughlin, M. Kyula, J.N. Wilkinson, M.J. Pencavel, T. Mansfield, D. Roulstone, V. Seth, R. Halle, M. Somaiah, N. Boult, J.K. Robinson, S.P. Pandha, H.S. Vile, R.G. Melcher, A.A. Harris, P.A. Harrington, K.J. (2018). Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. Sci transl med, Vol.10 (425).  show abstract

Annels, N.E. Arif, M. Simpson, G.R. Denyer, M. Moller-Levet, C. Mansfield, D. Butler, R. Shafren, D. Au, G. Knowles, M. Harrington, K. Vile, R. Melcher, A. Pandha, H. (2018). Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus. Mol ther oncolytics, Vol.9, pp. 1-12.  show abstract

Ilett, E. Kottke, T. Thompson, J. Rajani, K. Zaidi, S. Evgin, L. Coffey, M. Ralph, C. Diaz, R. Pandha, H. Harrington, K. Selby, P. Bram, R. Melcher, A. Vile, R. (2017). Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene ther, Vol.24 (1), pp. 21-30.  show abstract

Kottke, T. Evgin, L. Shim, K.G. Rommelfanger, D. Boisgerault, N. Zaidi, S. Diaz, R.M. Thompson, J. Ilett, E. Coffey, M. Selby, P. Pandha, H. Harrington, K. Melcher, A. Vile, R. (2017). Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. Cancer immunol res, Vol.5 (11), pp. 1029-1045.  show abstract

Cockle, J.V. Brüning-Richardson, A. Scott, K.J. Thompson, J. Kottke, T. Morrison, E. Ismail, A. Carcaboso, A.M. Rose, A. Selby, P. Conner, J. Picton, S. Short, S. Vile, R. Melcher, A. Ilett, E. (2017). Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Mol ther oncolytics, Vol.5, pp. 75-86.  show abstract

Rajani, K. Parrish, C. Kottke, T. Thompson, J. Zaidi, S. Ilett, L. Shim, K.G. Diaz, R.-. Pandha, H. Harrington, K. Coffey, M. Melcher, A. Vile, R. (2016). Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol ther, Vol.24 (1), pp. 166-174.  show abstract

Mansfield, D.C. Kyula, J.N. Rosenfelder, N. Chao-Chu, J. Kramer-Marek, G. Khan, A.A. Roulstone, V. McLaughlin, M. Melcher, A.A. Vile, R.G. Pandha, H.S. Khoo, V. Harrington, K.J. (2016). Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene ther, Vol.23 (4), pp. 357-368.  show abstract

Cockle, J.V. Rajani, K. Zaidi, S. Kottke, T. Thompson, J. Diaz, R.M. Shim, K. Peterson, T. Parney, I.F. Short, S. Selby, P. Ilett, E. Melcher, A. Vile, R. (2016). Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro oncol, Vol.18 (4), pp. 518-527.  show abstract

Holyoake, D.L. Ward, E. Grose, D. McIntosh, D. Sebag-Montefiore, D. Radhakrishna, G. Patel, N. Silva, M. Mukherjee, S. Strauss, V.Y. Odondi, L. Fokas, E. Melcher, A. Hawkins, M.A. (2016). A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol. Bmc cancer, Vol.16 (1), p. 728.  show abstract

Kottke, T. Shim, K.G. Alonso-Camino, V. Zaidi, S. Maria Diaz, R. Pulido, J. Thompson, J. Rajani, K.R. Evgin, L. Ilett, E. Pandha, H. Harrington, K. Selby, P. Melcher, A. Vile, R. (2016). Immunogenicity of self tumor associated proteins is enhanced through protein truncation. Mol ther oncolytics, Vol.3, p. 16030.  show abstract

Simpson, G.R. Relph, K. Harrington, K. Melcher, A. Pandha, H. (2016). Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic virother, Vol.5, pp. 1-13.  show abstract

Blanchard, M. Shim, K.G. Grams, M.P. Rajani, K. Diaz, R.M. Furutani, K.M. Thompson, J. Olivier, K.R. Park, S.S. Markovic, S.N. Pandha, H. Melcher, A. Harrington, K. Zaidi, S. Vile, R. (2015). Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. Int j radiat oncol biol phys, Vol.93 (3), pp. 577-587.  show abstract

Seth, R. Khan, A.A. Pencavel, T.D. Wilkinson, M.J. Kyula, J.N. Simpson, G. Pandha, H. Melcher, A. Vile, R. Harris, P.A. Harrington, K.J. (2015). Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma. Plast reconstr surg, Vol.135 (2), pp. 475-487.  show abstract

Turnbull, S. West, E.J. Scott, K.J. Appleton, E. Melcher, A. Ralph, C. (2015). Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. Viruses, Vol.7 (12), pp. 6291-6312.  show abstract

El-Sherbiny, Y.M. Holmes, T.D. Wetherill, L.F. Black, E.V. Wilson, E.B. Phillips, S.L. Scott, G.B. Adair, R.A. Dave, R. Scott, K.J. Morgan, R.S. Coffey, M. Toogood, G.J. Melcher, A.A. Cook, G.P. (2015). Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clin exp immunol, Vol.180 (1), pp. 98-107.  show abstract

Roulstone, V. Pedersen, M. Kyula, J. Mansfield, D. Khan, A.A. McEntee, G. Wilkinson, M. Karapanagiotou, E. Coffey, M. Marais, R. Jebar, A. Errington-Mais, F. Melcher, A. Vile, R. Pandha, H. McLaughlin, M. Harrington, K.J. (2015). BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. Mol ther, Vol.23 (5), pp. 931-942.  show abstract

Zaidi, S. Blanchard, M. Shim, K. Ilett, E. Rajani, K. Parrish, C. Boisgerault, N. Kottke, T. Thompson, J. Celis, E. Pulido, J. Selby, P. Pandha, H. Melcher, A. Harrington, K. Vile, R. (2015). Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents. Mol ther, Vol.23 (5), pp. 845-856.  show abstract

Jebar, A.H. Errington-Mais, F. Vile, R.G. Selby, P.J. Melcher, A.A. Griffin, S. (2015). Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. J gen virol, Vol.96 (Pt 7), pp. 1533-1550.  show abstract

Parrish, C. Scott, G.B. Migneco, G. Scott, K.J. Steele, L.P. Ilett, E. West, E.J. Hall, K. Selby, P.J. Buchanan, D. Varghese, A. Cragg, M.S. Coffey, M. Hillmen, P. Melcher, A.A. Errington-Mais, F. (2015). Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, Vol.29 (9), pp. 1799-1810.  show abstract

Roulstone, V. Khan, K. Pandha, H.S. Rudman, S. Coffey, M. Gill, G.M. Melcher, A.A. Vile, R. Harrington, K.J. de Bono, J. Spicer, J. (2015). Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin cancer res, Vol.21 (6), pp. 1305-1312.  show abstract

Cockle, J.V. Picton, S. Levesley, J. Ilett, E. Carcaboso, A.M. Short, S. Steel, L.P. Melcher, A. Lawler, S.E. Brüning-Richardson, A. (2015). Cell migration in paediatric glioma; characterisation and potential therapeutic targeting. Br j cancer, Vol.112 (4), pp. 693-703.  show abstract

Appleton, E.S. Turnbull, S. Ralph, C. West, E. Scott, K. Harrington, K. Pandha, H. Melcher, A. (2015). Talimogene laherparepvec in the treatment of melanoma. Expert opin biol ther, Vol.15 (10), pp. 1517-1530.  show abstract

Jennings, V.A. Ilett, E.J. Scott, K.J. West, E.J. Vile, R. Pandha, H. Harrington, K. Young, A. Hall, G.D. Coffey, M. Selby, P. Errington-Mais, F. Melcher, A.A. (2014). Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int j cancer, Vol.134 (5), pp. 1091-1101.  show abstract

Ilett, E. Kottke, T. Donnelly, O. Thompson, J. Willmon, C. Diaz, R. Zaidi, S. Coffey, M. Selby, P. Harrington, K. Pandha, H. Melcher, A. Vile, R. (2014). Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol ther, Vol.22 (10), pp. 1851-1863.  show abstract

Alonso-Camino, V. Rajani, K. Kottke, T. Rommelfanger-Konkol, D. Zaidi, S. Thompson, J. Pulido, J. Ilett, E. Donnelly, O. Selby, P. Pandha, H. Melcher, A. Harrington, K. Diaz, R.M. Vile, R. (2014). The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol ther, Vol.22 (11), pp. 1936-1948.  show abstract

Alonso-Camino, V. Rajani, K. Kottke, T. Rommelfanger-Konkol, D. Zaidi, S. Thompson, J. Pulido, J. Ilett, E. Donnelly, O. Selby, P. Pandha, H. Melcher, A. Harrington, K. Diaz, R.M. Vile, R. (2014). The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site. Molecular therapy, Vol.22 (11), pp. 1936-1948.

Kyula, J.N. Khan, A.A. Mansfield, D. Karapanagiotou, E.M. McLaughlin, M. Roulstone, V. Zaidi, S. Pencavel, T. Touchefeu, Y. Seth, R. Chen, N.G. Yu, Y.A. Zhang, Q. Melcher, A.A. Vile, R.G. Pandha, H.S. Ajaz, M. Szalay, A.A. Harrington, K.J. (2014). Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, Vol.33 (13), pp. 1700-1712.  show abstract

Bradley, S. Jakes, A.D. Harrington, K. Pandha, H. Melcher, A. Errington-Mais, F. (2014). Applications of coxsackievirus A21 in oncology. Oncolytic virother, Vol.3, pp. 47-55.  show abstract

Donnelly, O.G. Errington-Mais, F. Steele, L. Hadac, E. Jennings, V. Scott, K. Peach, H. Phillips, R.M. Bond, J. Pandha, H. Harrington, K. Vile, R. Russell, S. Selby, P. Melcher, A.A. (2013). Measles virus causes immunogenic cell death in human melanoma. Gene ther, Vol.20 (1), pp. 7-15.  show abstract

Mansfield, D. Pencavel, T. Kyula, J.N. Zaidi, S. Roulstone, V. Thway, K. Karapanagiotou, L. Khan, A.A. McLaughlin, M. Touchefeu, Y. Seth, R. Melcher, A.A. Vile, R.G. Pandha, H.S. Harrington, K.J. (2013). Oncolytic Vaccinia virus and radiotherapy in head and neck cancer. Oral oncol, Vol.49 (2), pp. 108-118.  show abstract

Roulstone, V. Twigger, K. Zaidi, S. Pencavel, T. Kyula, J.N. White, C. McLaughlin, M. Seth, R. Karapanagiotou, E.M. Mansfield, D. Coffey, M. Nuovo, G. Vile, R.G. Pandha, H.S. Melcher, A.A. Harrington, K.J. (2013). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene ther, Vol.20 (5), pp. 521-528.  show abstract

Cockle, J.V. Picton, S.V. Melcher, A. (2013). Future clinical potential of oncolytic virotherapy for pediatric CNS tumors. Cns oncol, Vol.2 (4), pp. 307-310.

Donnelly, O. Harrington, K. Melcher, A. Pandha, H. (2013). Live viruses to treat cancer. J r soc med, Vol.106 (8), pp. 310-314.  show abstract

Boisgerault, N. Kottke, T. Pulido, J. Thompson, J. Diaz, R.M. Rommelfanger-Konkol, D. Embry, A. Saenz, D. Poeschla, E. Pandha, H. Harrington, K. Melcher, A. Selby, P. Vile, R. (2013). Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol ther, Vol.21 (8), pp. 1507-1516.  show abstract

Kottke, T. Boisgerault, N. Diaz, R.M. Donnelly, O. Rommelfanger-Konkol, D. Pulido, J. Thompson, J. Mukhopadhyay, D. Kaspar, R. Coffey, M. Pandha, H. Melcher, A. Harrington, K. Selby, P. Vile, R. (2013). Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat med, Vol.19 (12), pp. 1625-1631.  show abstract

Adair, R.A. Scott, K.J. Fraser, S. Errington-Mais, F. Pandha, H. Coffey, M. Selby, P. Cook, G.P. Vile, R. Harrington, K.J. Toogood, G. Melcher, A.A. (2013). Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int j cancer, Vol.132 (10), pp. 2327-2338.  show abstract

Tai, L.-. Zhang, J. Scott, K.J. de Souza, C.T. Alkayyal, A.A. Ananth, A.A. Sahi, S. Adair, R.A. Mahmoud, A.B. Sad, S. Bell, J.C. Makrigiannis, A.P. Melcher, A.A. Auer, R.C. (2013). Perioperative influenza vaccination reduces postoperative metastatic disease by reversing surgery-induced dysfunction in natural killer cells. Clin cancer res, Vol.19 (18), pp. 5104-5115.  show abstract

Karapanagiotou, E.M. Roulstone, V. Twigger, K. Ball, M. Tanay, M. Nutting, C. Newbold, K. Gore, M.E. Larkin, J. Syrigos, K.N. Coffey, M. Thompson, B. Mettinger, K. Vile, R.G. Pandha, H.S. Hall, G.D. Melcher, A.A. Chester, J. Harrington, K.J. (2012). Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin cancer res, Vol.18 (7), pp. 2080-2089.  show abstract

Donnelly, O.G. Errington-Mais, F. Prestwich, R. Harrington, K. Pandha, H. Vile, R. Melcher, A.A. (2012). Recent clinical experience with oncolytic viruses. Curr pharm biotechnol, Vol.13 (9), pp. 1834-1841.  show abstract

Donnelly, O. Vile, R. Pandha, H. Harrington, K. Melcher, A. (2012). The hitchhiker's guide to virotherapy. Oncotarget, Vol.3 (8), pp. 735-736.

Nuovo, G.J. Garofalo, M. Valeri, N. Roulstone, V. Volinia, S. Cohn, D.E. Phelps, M. Harrington, K.J. Vile, R. Melcher, A. Galanis, E. Sehl, S. Adair, R. Scott, K. Rose, A. Toogood, G. Coffey, M.C. (2012). Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod pathol, Vol.25 (10), pp. 1333-1344.  show abstract

Kyula, J.N. Roulstone, V. Karapanagiotou, E.M. Melcher, A.A. Harrington, K.J. (2012). Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert opin biol ther, Vol.12 (12), pp. 1669-1678.  show abstract

Adair, R.A. Roulstone, V. Scott, K.J. Morgan, R. Nuovo, G.J. Fuller, M. Beirne, D. West, E.J. Jennings, V.A. Rose, A. Kyula, J. Fraser, S. Dave, R. Anthoney, D.A. Merrick, A. Prestwich, R. Aldouri, A. Donnelly, O. Pandha, H. Coffey, M. Selby, P. Vile, R. Toogood, G. Harrington, K. Melcher, A.A. (2012). Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci transl med, Vol.4 (138), p. 138ra77.  show abstract

Pulido, J. Kottke, T. Thompson, J. Galivo, F. Wongthida, P. Diaz, R.M. Rommelfanger, D. Ilett, E. Pease, L. Pandha, H. Harrington, K. Selby, P. Melcher, A. Vile, R. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat biotechnol, Vol.30 (4), pp. 337-343.  show abstract

Twigger, K. Roulstone, V. Kyula, J. Karapanagiotou, E.M. Syrigos, K.N. Morgan, R. White, C. Bhide, S. Nuovo, G. Coffey, M. Thompson, B. Jebar, A. Errington, F. Melcher, A.A. Vile, R.G. Pandha, H.S. Harrington, K.J. (2012). Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. Bmc cancer, Vol.12, p. 368.  show abstract

Simpson, G.R. Horvath, A. Annels, N.E. Pencavel, T. Metcalf, S. Seth, R. Peschard, P. Price, T. Coffin, R.S. Mostafid, H. Melcher, A.A. Harrington, K.J. Pandha, H.S. (2012). Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br j cancer, Vol.106 (3), pp. 496-507.  show abstract

Ilett, E.J. Bárcena, M. Errington-Mais, F. Griffin, S. Harrington, K.J. Pandha, H.S. Coffey, M. Selby, P.J. Limpens, R.W. Mommaas, M. Hoeben, R.C. Vile, R.G. Melcher, A.A. (2011). Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin cancer res, Vol.17 (9), pp. 2767-2776.  show abstract

Willmon, C. Diaz, R.M. Wongthida, P. Galivo, F. Kottke, T. Thompson, J. Albelda, S. Harrington, K. Melcher, A. Vile, R. (2011). Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol ther, Vol.19 (1), pp. 140-149.  show abstract

Heinemann, L. Simpson, G.R. Boxall, A. Kottke, T. Relph, K.L. Vile, R. Melcher, A. Prestwich, R. Harrington, K.J. Morgan, R. Pandha, H.S. (2011). Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. Bmc cancer, Vol.11, p. 221.  show abstract

West, E.J. Scott, K.J. Jennings, V.A. Melcher, A.A. (2011). Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. Br j cancer, Vol.105 (6), pp. 787-795.  show abstract

Kottke, T. Chester, J. Ilett, E. Thompson, J. Diaz, R. Coffey, M. Selby, P. Nuovo, G. Pulido, J. Mukhopadhyay, D. Pandha, H. Harrington, K. Melcher, A. Vile, R. (2011). Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol ther, Vol.19 (10), pp. 1802-1812.  show abstract

Kottke, T. Errington, F. Pulido, J. Galivo, F. Thompson, J. Wongthida, P. Diaz, R.M. Chong, H. Ilett, E. Chester, J. Pandha, H. Harrington, K. Selby, P. Melcher, A. Vile, R. (2011). Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat med, Vol.17 (7), pp. 854-859.  show abstract

Steele, L. Errington, F. Prestwich, R. Ilett, E. Harrington, K. Pandha, H. Coffey, M. Selby, P. Vile, R. Melcher, A. (2011). Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Mol cancer, Vol.10, p. 20.  show abstract

Harrington, K.J. Karapanagiotou, E.M. Roulstone, V. Twigger, K.R. White, C.L. Vidal, L. Beirne, D. Prestwich, R. Newbold, K. Ahmed, M. Thway, K. Nutting, C.M. Coffey, M. Harris, D. Vile, R.G. Pandha, H.S. Debono, J.S. Melcher, A.A. (2010). Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin cancer res, Vol.16 (11), pp. 3067-3077.  show abstract

Hingorani, M. Spitzweg, C. Vassaux, G. Newbold, K. Melcher, A. Pandha, H. Vile, R. Harrington, K. (2010). The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr cancer drug targets, Vol.10 (2), pp. 242-267.  show abstract

Kottke, T. Hall, G. Pulido, J. Diaz, R.M. Thompson, J. Chong, H. Selby, P. Coffey, M. Pandha, H. Chester, J. Melcher, A. Harrington, K. Vile, R. (2010). Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J clin invest, Vol.120 (5), pp. 1551-1560.  show abstract

Pencavel, T. Seth, R. Hayes, A. Melcher, A. Pandha, H. Vile, R. Harrington, K.J. (2010). Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?. Gene ther, Vol.17 (8), pp. 949-960.  show abstract

Hingorani, M. White, C.L. Zaidi, S. Pandha, H.S. Melcher, A.A. Bhide, S.A. Nutting, C.M. Syrigos, K.N. Vile, R.G. Vassaux, G. Harrington, K.J. (2010). Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair. Mol ther, Vol.18 (9), pp. 1599-1605.  show abstract

Heinemann, L. Simpson, G.R. Annels, N.E. Vile, R. Melcher, A. Prestwich, R. Harrington, K.J. Pandha, H.S. (2010). The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis. Mol ther, Vol.18 (12), pp. 2085-2093.  show abstract

Comins, C. Spicer, J. Protheroe, A. Roulstone, V. Twigger, K. White, C.M. Vile, R. Melcher, A. Coffey, M.C. Mettinger, K.L. Nuovo, G. Cohn, D.E. Phelps, M. Harrington, K.J. Pandha, H.S. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin cancer res, Vol.16 (22), pp. 5564-5572.  show abstract

Harrington, K.J. Vile, R.G. Melcher, A. Chester, J. Pandha, H.S. (2010). Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine growth factor rev, Vol.21 (2-3), pp. 91-98.  show abstract

Kottke, T. Pulido, J. Thompson, J. Sanchez-Perez, L. Chong, H. Calderwood, S.K. Selby, P. Harrington, K. Strome, S.E. Melcher, A. Vile, R.G. (2009). Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer res, Vol.69 (19), pp. 7767-7774.  show abstract

Pandha, H.S. Heinemann, L. Simpson, G.R. Melcher, A. Prestwich, R. Errington, F. Coffey, M. Harrington, K.J. Morgan, R. (2009). Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin cancer res, Vol.15 (19), pp. 6158-6166.  show abstract

Agrawal, V.K. Copeland, K.M. Barbachano, Y. Rahim, A. Seth, R. White, C.L. Hingorani, M. Nutting, C.M. Kelly, M. Harris, P. Pandha, H. Melcher, A.A. Vile, R.G. Porter, C. Harrington, K.J. (2009). Microvascular free tissue transfer for gene delivery: in vivo evaluation of different routes of plasmid and adenoviral delivery. Gene ther, Vol.16 (1), pp. 78-92.  show abstract

Prestwich, R.J. Errington, F. Steele, L.P. Ilett, E.J. Morgan, R.S. Harrington, K.J. Pandha, H.S. Selby, P.J. Vile, R.G. Melcher, A.A. (2009). Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J immunol, Vol.183 (7), pp. 4312-4321.  show abstract

Prestwich, R.J. Ilett, E.J. Errington, F. Diaz, R.M. Steele, L.P. Kottke, T. Thompson, J. Galivo, F. Harrington, K.J. Pandha, H.S. Selby, P.J. Vile, R.G. Melcher, A.A. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin cancer res, Vol.15 (13), pp. 4374-4381.  show abstract

West, E. Morgan, R. Scott, K. Merrick, A. Lubenko, A. Pawson, D. Selby, P. Hatfield, P. Prestwich, R. Fraser, S. Eves, D. Anthoney, A. Twelves, C. Beirne, D. Patel, P. O'Donnell, D. Watt, S. Waller, M. Dietz, A. Robinson, P. Melcher, A. (2009). Clinical grade OK432-activated dendritic cells: in vitro characterization and tracking during intralymphatic delivery. J immunother, Vol.32 (1), pp. 66-78.  show abstract

Prestwich, R.J. Scott, K.J. Brown, J. Harnden, P. Whelan, P. Cartledge, J. O'Donnell, D. Pandha, H.S. Selby, P.J. Banks, R.E. Merrick, A.E. Melcher, A.A. (2009). The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma. Bju int, Vol.103 (6), pp. 740-746.  show abstract

Ilett, E.J. Prestwich, R.J. Kottke, T. Errington, F. Thompson, J.M. Harrington, K.J. Pandha, H.S. Coffey, M. Selby, P.J. Vile, R.G. Melcher, A.A. (2009). Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity. Gene ther, Vol.16 (5), pp. 689-699.  show abstract

Willmon, C. Harrington, K. Kottke, T. Prestwich, R. Melcher, A. Vile, R. (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol ther, Vol.17 (10), pp. 1667-1676.  show abstract

Prestwich, R.J. Errington, F. Diaz, R.M. Pandha, H.S. Harrington, K.J. Melcher, A.A. Vile, R.G. (2009). The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum gene ther, Vol.20 (10), pp. 1119-1132.  show abstract

Kottke, T. Thompson, J. Diaz, R.M. Pulido, J. Willmon, C. Coffey, M. Selby, P. Melcher, A. Harrington, K. Vile, R.G. (2009). Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin cancer res, Vol.15 (2), pp. 561-569.  show abstract

Saunders, M. Anthoney, A. Coffey, M. Mettinger, K. Thompson, B. Melcher, A. Nutting, C.M. Harrington, K. (2009). Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J clin oncol, Vol.27 (15_suppl), p. e14514.  show abstract

Karapanagiotou, E. Pandha, H.S. Hall, G. Chester, J. Melcher, A. Coffey, M. de Bono, J. Gore, M.E. Nutting, C.M. Harrington, K.J. (2009). Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers. J clin oncol, Vol.27 (15_suppl), p. e14519.  show abstract

Qiao, J. Wang, H. Kottke, T. White, C. Twigger, K. Diaz, R.M. Thompson, J. Selby, P. de Bono, J. Melcher, A. Pandha, H. Coffey, M. Vile, R. Harrington, K. (2008). Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin cancer res, Vol.14 (1), pp. 259-269.  show abstract

Twigger, K. Vidal, L. White, C.L. De Bono, J.S. Bhide, S. Coffey, M. Thompson, B. Vile, R.G. Heinemann, L. Pandha, H.S. Errington, F. Melcher, A.A. Harrington, K.J. (2008). Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin cancer res, Vol.14 (3), pp. 912-923.  show abstract

Qiao, J. Kottke, T. Willmon, C. Galivo, F. Wongthida, P. Diaz, R.M. Thompson, J. Ryno, P. Barber, G.N. Chester, J. Selby, P. Harrington, K. Melcher, A. Vile, R.G. (2008). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat med, Vol.14 (1), pp. 37-44.  show abstract

Hingorani, M. White, C.L. Merron, A. Peerlinck, I. Gore, M.E. Slade, A. Scott, S.D. Nutting, C.M. Pandha, H.S. Melcher, A.A. Vile, R.G. Vassaux, G. Harrington, K.J. (2008). Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors. Cancer res, Vol.68 (23), pp. 9771-9778.  show abstract

Vidal, L. Pandha, H.S. Yap, T.A. White, C.L. Twigger, K. Vile, R.G. Melcher, A. Coffey, M. Harrington, K.J. DeBono, J.S. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin cancer res, Vol.14 (21), pp. 7127-7137.  show abstract

Errington, F. Steele, L. Prestwich, R. Harrington, K.J. Pandha, H.S. Vidal, L. de Bono, J. Selby, P. Coffey, M. Vile, R. Melcher, A. (2008). Reovirus activates human dendritic cells to promote innate antitumor immunity. J immunol, Vol.180 (9), pp. 6018-6026.  show abstract

Hingorani, M. White, C.L. Zaidi, S. Merron, A. Peerlinck, I. Gore, M.E. Nutting, C.M. Pandha, H.S. Melcher, A.A. Vile, R.G. Vassaux, G. Harrington, K.J. (2008). Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapy. Clin cancer res, Vol.14 (15), pp. 4915-4924.  show abstract

Hill, K.S. Errington, F. Steele, L.P. Merrick, A. Morgan, R. Selby, P.J. Georgopoulos, N.T. O'Donnell, D.M. Melcher, A.A. (2008). OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J immunol, Vol.181 (5), pp. 3108-3115.  show abstract

White, C.L. Menghistu, T. Twigger, K.R. Searle, P.F. Bhide, S.A. Vile, R.G. Melcher, A.A. Pandha, H.S. Harrington, K.J. (2008). Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo. Gene ther, Vol.15 (6), pp. 424-433.  show abstract

Prestwich, R.J. Errington, F. Hatfield, P. Merrick, A.E. Ilett, E.J. Selby, P.J. Melcher, A.A. (2008). The immune system--is it relevant to cancer development, progression and treatment?. Clin oncol (r coll radiol), Vol.20 (2), pp. 101-112.  show abstract

White, C.L. Twigger, K.R. Vidal, L. De Bono, J.S. Coffey, M. Heinemann, L. Morgan, R. Merrick, A. Errington, F. Vile, R.G. Melcher, A.A. Pandha, H.S. Harrington, K.J. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene ther, Vol.15 (12), pp. 911-920.  show abstract

Merrick, A. Diaz, R.M. O'Donnell, D. Selby, P. Vile, R. Melcher, A. (2008). Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapy. Cancer immunol immunother, Vol.57 (6), pp. 897-906.  show abstract

Prestwich, R.J. Harrington, K.J. Vile, R.G. Melcher, A.A. (2008). Immunotherapeutic potential of oncolytic virotherapy. Lancet oncol, Vol.9 (7), pp. 610-612.

Kottke, T. Galivo, F. Wongthida, P. Maria Diaz, R. Thompson, J. Jevremovic, D. Barber, G.N. Hall, G. Chester, J. Selby, P. Harrington, K. Melcher, A. Vile, R.G. (2008). Treg Depletion-enhanced IL-2 Treatment Facilitates Therapy of Established Tumors Using Systemically Delivered Oncolytic Virus. Mol ther, Vol.16 (7), pp. 1217-1226.  show abstract

Harrington, K.J. Melcher, A. Vassaux, G. Pandha, H.S. Vile, R.G. (2008). Exploiting synergies between radiation and oncolytic viruses. Curr opin mol ther, Vol.10 (4), pp. 362-370.  show abstract

Comins, C. Heinemann, L. Harrington, K. Melcher, A. De Bono, J. Pandha, H. (2008). Reovirus: viral therapy for cancer 'as nature intended'. Clin oncol (r coll radiol), Vol.20 (7), pp. 548-554.  show abstract

Errington, F. White, C.L. Twigger, K.R. Rose, A. Scott, K. Steele, L. Ilett, L.J. Prestwich, R. Pandha, H.S. Coffey, M. Selby, P. Vile, R. Harrington, K.J. Melcher, A.A. (2008). Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene ther, Vol.15 (18), pp. 1257-1270.  show abstract

Hatfield, P. Merrick, A.E. West, E. O'Donnell, D. Selby, P. Vile, R. Melcher, A.A. (2008). Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. J immunother, Vol.31 (7), pp. 620-632.  show abstract

Prestwich, R.J. Harrington, K.J. Pandha, H.S. Vile, R.G. Melcher, A.A. Errington, F. (2008). Oncolytic viruses: a novel form of immunotherapy. Expert rev anticancer ther, Vol.8 (10), pp. 1581-1588.  show abstract

Kottke, T. Diaz, R.M. Kaluza, K. Pulido, J. Galivo, F. Wongthida, P. Thompson, J. Willmon, C. Barber, G.N. Chester, J. Selby, P. Strome, S. Harrington, K. Melcher, A. Vile, R.G. (2008). Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol ther, Vol.16 (12), pp. 1910-1918.  show abstract

Prestwich, R.J. Errington, F. Ilett, E.J. Morgan, R.S. Scott, K.J. Kottke, T. Thompson, J. Morrison, E.E. Harrington, K.J. Pandha, H.S. Selby, P.J. Vile, R.G. Melcher, A.A. (2008). Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin cancer res, Vol.14 (22), pp. 7358-7366.  show abstract

Prestwich, R.J. Errington, F. Harrington, K.J. Pandha, H.S. Selby, P. Melcher, A. (2008). Oncolytic viruses: do they have a role in anti-cancer therapy?. Clin med oncol, Vol.2, pp. 83-96.  show abstract

Hingorani, M. White, C.L. Agrawal, V.K. Vidal, L. Melcher, A. Harrington, K.J. (2007). Combining radiation and cancer gene therapy: a potential marriage of physical and biological targeting?. Curr cancer drug targets, Vol.7 (4), pp. 389-409.  show abstract

Harris, D. Vidal, L. Melcher, A. Newbold, K. Anthony, A. Karavasilis, V. Agarwal, R. White, C. Twigger, K. Coffey, M. Mettinger, K. Thompson, B. Pandha, H. De-Bono, J. Harrington, K. (2007). A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies. Molecular cancer therapeutics, Vol.6 (12), pp. 3458S-3458S.

Kottke, T. Sanchez-Perez, L. Diaz, R.M. Thompson, J. Chong, H. Harrington, K. Calderwood, S.K. Pulido, J. Georgopoulos, N. Selby, P. Melcher, A. Vile, R. (2007). Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer res, Vol.67 (24), pp. 11970-11979.  show abstract

Georgopoulos, N.T. Merrick, A. Scott, N. Selby, P.J. Melcher, A. Trejdosiewicz, L.K. (2007). CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int j cancer, Vol.121 (6), pp. 1373-1381.  show abstract

Craven, I. Crellin, A. Cooper, R. Melcher, A. Byrne, P. Sebag-Montefiore, D. (2007). Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br j cancer, Vol.97 (10), pp. 1333-1337.  show abstract

Errington, F. Jones, J. Merrick, A. Bateman, A. Harrington, K. Gough, M. O'Donnell, D. Selby, P. Vile, R. Melcher, A. (2006). Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene ther, Vol.13 (2), pp. 138-149.  show abstract

Errington, F. Bateman, A. Kottke, T. Thompson, J. Harrington, K. Merrick, A. Hatfield, P. Selby, P. Vile, R. Melcher, A. (2006). Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin cancer res, Vol.12 (4), pp. 1333-1341.  show abstract

Hatfield, P. Merrick, A. Harrington, K. Vile, R. Bateman, A. Selby, P. Melcher, A. (2005). Radiation-induced cell death and dendritic cells: potential for cancer immunotherapy?. Clin oncol (r coll radiol), Vol.17 (1), pp. 1-11.  show abstract

Merrick, A. Errington, F. Milward, K. O'Donnell, D. Harrington, K. Bateman, A. Pandha, H. Vile, R. Morrison, E. Selby, P. Melcher, A. (2005). Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming. Br j cancer, Vol.92 (8), pp. 1450-1458.  show abstract

Daniels, G.A. Sanchez-Perez, L. Diaz, R.M. Kottke, T. Thompson, J. Lai, M. Gough, M. Karim, M. Bushell, A. Chong, H. Melcher, A. Harrington, K. Vile, R.G. (2004). A simple method to cure established tumors by inflammatory killing of normal cells. Nat biotechnol, Vol.22 (9), pp. 1125-1132.  show abstract

Melcher, A.A. Sebag-Montefiore, D. (2003). Concurrent chemoradiotherapy for squamous cell carcinoma of the anus using a shrinking field radiotherapy technique without a boost. Br j cancer, Vol.88 (9), pp. 1352-1357.  show abstract

Linardakis, E. Bateman, A. Phan, V. Ahmed, A. Gough, M. Olivier, K. Kennedy, R. Errington, F. Harrington, K.J. Melcher, A. Vile, R. (2002). Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer res, Vol.62 (19), pp. 5495-5504.  show abstract

Harrington, K.J. Bateman, A.R. Melcher, A.A. Ahmed, A. Vile, R.G. (2002). Cancer gene therapy: Part 1 Vector development and regulation of gene expression. Clin oncol (r coll radiol), Vol.14 (1), pp. 3-16.

Harrington, K.J. Melcher, A.A. Bateman, A.R. Ahmed, A. Vile, R.G. (2002). Cancer gene therapy: Part 2 Candidate transgenes and their clinical development. Clin oncol (r coll radiol), Vol.14 (2), pp. 148-169.

Melcher, A. Bateman, A. Harrington, K. Ahmed, A. Gough, M. Vile, R. (2002). Dendritic cells for the immunotherapy of cancer. Clin oncol (r coll radiol), Vol.14 (3), pp. 185-192.


Book Chapters

Comins, C. Simpson, G.R. Relph, K. Harrington, K.J. Melcher, A. Pandha, H. (2014). Reoviral Therapy for Cancer. Gene Therapy of Cancer. (pp. 185-198). Elsevier.


Conferences

Cockle, J.Bjerke, L.Mackay, A.Grabovska, Y.Burford, A.Molinari, V.Pereira, R.Boult, J.Robinson, S.Carvalho, D.M.Clarke, M.Titley, I.Yara, E.Straathof, K.Wennerberg, E.Becher, O.Castro, M.Melcher, A.Jones, C. (2022). EXPLORING AND MODULATING THE TUMOUR IMMUNE MICROENVIRONMENT TO FACILITATE THE SELECTION OF IMMUNOTHERAPIES FOR PAEDIATRIC-TYPE DIFFUSE HIGH-GRADE GLIOMA, Presented at 20th International Symposium on Pediatric Neuro-Oncology (ISPNO) / Annual Meeting of the Brain-Tumor-Group-of-SIOP-Europe (SIOPE-BTG), GERMANY, Hamburg. NEURO-ONCOLOGY, Vol.24, pp.83-2.

In this section

Professional activities Publications